Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Declines By 25.4%

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) was the recipient of a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 708,700 shares, a drop of 25.4% from the February 28th total of 950,600 shares. Based on an average daily volume of 278,000 shares, the short-interest ratio is presently 2.5 days. Approximately 3.3% of the shares of the stock are short sold.

MAIA Biotechnology Stock Performance

NYSEAMERICAN MAIA traded down $0.03 during trading on Tuesday, reaching $1.50. 72,078 shares of the company traded hands, compared to its average volume of 236,448. MAIA Biotechnology has a 1-year low of $1.46 and a 1-year high of $5.99. The firm has a market capitalization of $39.24 million, a P/E ratio of -1.09 and a beta of 0.20. The stock has a 50 day moving average price of $1.81.

Institutional Trading of MAIA Biotechnology

Several institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd bought a new position in MAIA Biotechnology during the 3rd quarter valued at about $31,000. Jane Street Group LLC acquired a new stake in shares of MAIA Biotechnology during the fourth quarter worth approximately $77,000. Finally, Geode Capital Management LLC increased its holdings in shares of MAIA Biotechnology by 22.9% during the third quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock worth $541,000 after buying an additional 35,821 shares in the last quarter. Institutional investors and hedge funds own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.